Belimumab Dosage
Medically reviewed by Drugs.com. Last updated on Apr 5, 2024.
Applies to the following strengths: 200 mg/mL; 120 mg; 400 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Systemic Lupus Erythematosus
IV: 10 mg/kg IV every 2 weeks for the first 3 doses and every 4 weeks thereafter
Subcutaneous: 200 mg subcutaneously once a week
Comments:
- Subcutaneous dosing is not based on weight.
- If transitioning from IV therapy to subcutaneous administration, the first subcutaneous dose should be administered 1 to 4 weeks after the last IV dose.
Use: For the treatment of patients with active systemic lupus erythematosus (SLE) who are receiving standard therapy
Usual Adult Dose for Lupus Nephritis
IV: 10 mg/kg IV every 2 weeks for the first 3 doses and every 4 weeks thereafter
Subcutaneous:
- As initial therapy: 400 mg subcutaneously once a week for 4 doses, then 200 mg subcutaneously once a week thereafter
Comments:
- Patients may transition from IV therapy to subcutaneous therapy any time after completion of the first 2 IV doses; if transitioning, the first subcutaneous dose of 200 mg should be administered 1 to 2 weeks after the last IV dose.
Use: For the treatment of patients with active lupus nephritis who are receiving standard therapy
Usual Pediatric Dose for Systemic Lupus Erythematosus
5 years and older: 10 mg/kg IV every 2 weeks for the first 3 doses and every 4 weeks thereafter
Uses:
- For the treatment of patients with active SLE who are receiving standard therapy
- For the treatment of patients with active lupus nephritis who are receiving standard therapy
Usual Pediatric Dose for Lupus Nephritis
5 years and older: 10 mg/kg IV every 2 weeks for the first 3 doses and every 4 weeks thereafter
Uses:
- For the treatment of patients with active SLE who are receiving standard therapy
- For the treatment of patients with active lupus nephritis who are receiving standard therapy
Renal Dose Adjustments
Renal dysfunction: No adjustment recommended
Liver Dose Adjustments
Liver dysfunction: No adjustment recommended
Precautions
CONTRAINDICATIONS:
- Previous anaphylaxis to the active component
Safety and efficacy of IV administration have not been established in patients younger than 5 years. Safety and efficacy of subcutaneous administration have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
IV Administration:
- May administer as an IV infusion in patients aged 5 years and older or as a subcutaneous injection in patients aged 18 years and older
- Vials are intended for IV use only (not for subcutaneous use); autoinjectors and prefilled syringes are intended for subcutaneous use only (not for IV use).
- This drug should be administered by health care providers prepared to manage anaphylaxis.
- Reconstitute, dilute, and administer as an IV infusion over 1 hour; do not administer as an IV push or bolus.
- The infusion rate may be slowed or interrupted if the patient develops an infusion reaction.
- Discontinue the infusion immediately if the patient has a serious hypersensitivity reaction.
- Do not infuse concomitantly in the same IV line with other agents.
- Monitor patients during infusion and for an appropriate period of time after IV administration of this drug.
- Before IV dosing, consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions.
Subcutaneous Administration:
- The first subcutaneous injection should be under the supervision of a health care professional.
- The health care provider should provide proper training in subcutaneous technique and education about signs/symptoms of hypersensitivity reactions.
- A patient may self-inject or the patient caregiver may administer this drug subcutaneously after the health care provider determines it is appropriate.
- Instruct the patient or caregiver to follow the directions for administration in the Instructions for Use.
- Administer as a subcutaneous injection in the abdomen or thigh; administer weekly, preferably on the same day each week.
- Remove the autoinjector or prefilled syringe from the refrigerator and allow it to sit at room temperature for 30 minutes before subcutaneous injection; do not warm in any other way.
- Do not use the autoinjector or prefilled syringe if dropped on a hard surface.
- When injecting in the same body region, use a different injection site for each injection; do not inject into areas where skin is tender, bruised, red, or hard.
- When a 400 mg dose is administered at the same site, administer the 2 individual 200 mg injections at least 5 cm (about 2 inches) apart.
- If a dose is missed, administer a dose as soon as remembered; thereafter, resume dosing on the usual day of administration or start a new weekly schedule from the day that the missed dose was administered.
Storage requirements:
IV Infusion:
- Unopened vials: Refrigerate at 2C to 8C (36 F to 46F); store in original carton until use to protect from light. Do not freeze; avoid exposure to heat.
- Before reconstitution, remove vial from refrigerator and allow to stand for 10 to 15 minutes for the vial to reach room temperature.
- Allow vial to sit at room temperature during reconstitution (usually complete within 10 to 15 minutes after adding sterile water but may take up to 30 minutes).
- Reconstituted solution: If not used immediately, protect from sunlight, and refrigerate at 2C to 8C (36 F to 46F).
- Diluted solution: Store at 2C to 8C (36 F to 46F) or room temperature.
- The total time from reconstitution to completion of infusion should not exceed 8 hours.
Subcutaneous Injection:
- Before dispensing: Refrigerate prefilled autoinjectors and prefilled syringes at 2C to 8C (36 F to 46F); keep in original carton until time of use to protect from light. Do not freeze or shake; avoid exposure to heat.
- After dispensing: Refrigerate prefilled autoinjectors and prefilled syringes at 2C to 8C (36 F to 46F); keep in original carton until time of use to protect from light. Do not freeze or shake; avoid exposure to heat.
- May store outside of refrigerator up to 30C (86F) for up to 12 hours if protected from sunlight; do not use and do not return to refrigerator if left out for more than 12 hours.
Reconstitution/preparation techniques:
- For IV use: This drug must be reconstituted and diluted before administration.
- The manufacturer product information should be consulted.
IV compatibility:
- Compatible: Sterile Water for Injection, USP; 0.9% Sodium Chloride Injection, USP (normal saline); 0.45% Sodium Chloride Injection, USP (half-normal saline); Lactated Ringer's Injection, USP
- No incompatibilities between this drug and polyvinylchloride or polyolefin bags have been observed.
- Incompatible: Dextrose IV solutions
- No physical or biochemical compatibility studies have been conducted to evaluate coadministration of this drug with other agents.
General:
- Limitations of Use: Efficacy has not been evaluated in patients with severe active CNS lupus; this drug should not be used in this situation.
- This drug should be used with caution in older adult patients (65 years and older).
Monitoring:
- General: For infusion-related reactions (during and after IV infusion)
- Hypersensitivity: For hypersensitivity reactions (during and after IV infusion)
- Psychiatric: Psychiatric status (before and during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use).
- Notify health care provider if signs/symptoms of an infection develop.
- Contact health care professional if new/worsening neurological symptoms (e.g., memory loss, confusion, dizziness/loss of balance, difficulty talking/walking, vision problems) occur.
- Hypersensitivity and infusion-related reactions (including wheezing, difficulty breathing, angioedema, rash, hypotension, bradycardia, headache) have been reported; notify health care provider immediately if symptoms of an allergic reaction occur during or after administration of this drug. Seek immediate medical care if a hypersensitivity reaction occurs.
- Delayed reactions that may include a combination of symptoms (e.g., rash, nausea, fatigue, muscle aches, headache, facial swelling) are possible and may occur after administration of this drug; contact health care provider.
- Contact health care provider if new/worsening depression, suicidal thoughts/behavior, or other mood changes occur.
- Do not receive live vaccines while taking this drug; response to vaccinations could be impaired by this drug.
- A pregnancy registry has been established to evaluate fetal outcomes of pregnant women with lupus exposed to this drug.
- Patients of childbearing potential: This drug may affect the immune system in infants of treated mothers; notify prescriber of a known/suspected pregnancy.
Frequently asked questions
More about belimumab
- Check interactions
- Compare alternatives
- Reviews (64)
- Side effects
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.